BioTuesdays

Category - Feature

Feature

Mazor’s odyssey to spine robotic surgery leader

By Len Zehr Since its founding 15 years ago, Mazor Robotics (NASDAQ, TASE:MZOR) has overcome challenges typical to medical device startups to become the leader and possibly the standard of care in spine robotics surgery...

October 31, 2017
Feature

Flex Pharma focused on 3 clinical readouts in 2018

By Len Zehr Flex Pharma (NASDAQ:FLKS) expects to report clinical readouts in 2018 from three Phase 2 studies of its anti-cramping drug candidate, FLX-787, in amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth...

October 24, 2017
Feature

Thera sees ibalizumab as company game changer

By Len Zehr If approved by the FDA in the next few months, ibalizumab for patients with multidrug resistant HIV has the potential to be a game changer for Theratechnologies (TSX:TH). The FDA accepted ibalizumab for...

October 17, 2017
Feature

Diffusion Pharma readies pivotal hypoxic GBM trial

By Len Zehr Diffusion Pharmaceuticals (NASDAQ:DFFN) expects to begin before the end of 2017 a pivotal clinical trial with its trans sodium crocetinate (TSC) lead compound to re-oxygenate oxygen-deprived tissue in...

October 3, 2017
Feature

In conversation with Hrishikesh Suresh of NeuroGate

By Len Zehr As CEO and one of three co-founders of upstart NeuroGate, Hrishikesh Suresh currently is completing his final year as a medical student at McMaster University in Hamilton, Ontario and plans to pursue a six...

September 26, 2017